These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20163864)

  • 1. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes.
    Wester ST; Lee WW; Shi W
    Ophthalmology; 2010 May; 117(5):1024-31. PubMed ID: 20163864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.
    Giannico AT; Lima L; Russ HH; Montiani-Ferreira F
    J Ocul Pharmacol Ther; 2013 Nov; 29(9):817-20. PubMed ID: 23981234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth.
    Yoelin S; Walt JG; Earl M
    Dermatol Surg; 2010 May; 36(5):638-49. PubMed ID: 20384751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.
    Smith S; Fagien S; Whitcup SM; Ledon F; Somogyi C; Weng E; Beddingfield FC
    J Am Acad Dermatol; 2012 May; 66(5):801-6. PubMed ID: 21899919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
    Harii K; Arase S; Tsuboi R; Weng E; Daniels S; VanDenburgh A
    Aesthetic Plast Surg; 2014 Apr; 38(2):451-60. PubMed ID: 24643895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement.
    Woodward JA; Haggerty CJ; Stinnett SS; Williams ZY
    J Cosmet Dermatol; 2010 Jun; 9(2):96-102. PubMed ID: 20618554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertrichosis of the eyelashes caused by bimatoprost.
    Tosti A; Pazzaglia M; Voudouris S; Tosti G
    J Am Acad Dermatol; 2004 Nov; 51(5 Suppl):S149-50. PubMed ID: 15577756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.
    Fagien S; Walt JG; Carruthers J; Cox SE; Wirta D; Weng E; Beddingfield FC
    Aesthet Surg J; 2013 Aug; 33(6):789-98. PubMed ID: 23873891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of trichotillomania with bimatoprost.
    Peabody T; Reitz S; Smith J; Teti B
    Optom Vis Sci; 2013 Jun; 90(6):e167-71. PubMed ID: 23645373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term utility and durability of the therapeutic effects of bimatoprost 0.03% for eyelash augmentation in healthy Asian subjects.
    Kwon O; Kim JY; Paik SH; Jeon HC; Jung YJ; Lee Y; Baek JH; Chun JH; Lee WS; Lee JY; Rogers JD; Halstead M; Eun HC
    Dermatology; 2014; 229(3):222-9. PubMed ID: 25228046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface.
    Bitton E; Courey C; Giancola P; Diaconu V; Wise J; Wittich W
    Clin Exp Optom; 2017 Nov; 100(6):583-589. PubMed ID: 28122407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost.
    Hart J; Shafranov G
    Am J Ophthalmol; 2004 Apr; 137(4):756-7. PubMed ID: 15059720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
    McCarey BE; Kapik BM; Kane FE;
    Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost.
    Tauchi M; Fuchs TA; Kellenberger AJ; Woodward DF; Paus R; Lütjen-Drecoll E
    Br J Dermatol; 2010 Jun; 162(6):1186-97. PubMed ID: 20346040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iris heterochromia and unilateral eyelash hypertrichosis.
    Rao RC; Ballard TN; Chen TC
    JAMA; 2015 May; 313(19):1967-8. PubMed ID: 25988467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.
    Brandt JD; VanDenburgh AM; Chen K; Whitcup SM;
    Ophthalmology; 2001 Jun; 108(6):1023-31; discussion 1032. PubMed ID: 11382623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced eyelashes: prescription and over-the-counter options.
    Jones D
    Aesthetic Plast Surg; 2011 Feb; 35(1):116-21. PubMed ID: 20730536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
    Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
    Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss.
    Ahluwalia GS
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S73-6. PubMed ID: 24326568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.